Barry J. Byrne, MD, PhD

The chief medical advisor at the Muscular Dystrophy Association provided perspective on the upcoming meeting and the conversations surrounding new therapeutics for diseases that once had little to nothing. [WATCH TIME: 4 minutes]

The chief medical advisor at the Muscular Dystrophy Association gave his reaction to Amicus Pharmaceuticals’ recently FDA approved 2-part therapy for patients living with Pompe disease. [WATCH TIME: 7 minutes]

Barry J. Byrne, MD, PhD, chief medical advisor, Muscular Dystrophy Association, calls for the prioritization of persons with neuromuscular diseases as early candidates for the COVID-19 vaccination implementation.

The chief medical advisor for the Muscular Dystrophy Association discussed the organization’s recent annual telethon and the efforts to inform the public about these diseases.

The chief medical advisor for the Muscular Dystrophy Association discussed the switch to virtual conferences and shared his insight on how the neuromuscular community can move forward amid COVID-19.

The chief medical advisor for the Muscular Dystrophy Association discussed how the ongoing novel coronavirus pandemic will have a lasting impact on the use of telemedicine in the neuromuscular community­­.

The chief medical advisor for the Muscular Dystrophy Association detailed his experience with the process of having to manage patients and conduct research amid the COVID-19 pandemic.

The chief medical advisor for the Muscular Dystrophy Association spoke about the process of keeping patients updated on new information and how the MDA has taken steps to ensure the neuromuscular community gets the correct information.

The chief medical advisor for the Muscular Dystrophy Association discussed how his approach to the management and care of patients with neuromuscular disease has been affected by the COVID-19 pandemic.